Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetic and Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Trial Profile

Pharmacokinetic and Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emixustat (Primary)
  • Indications Age-related macular degeneration
  • Focus Pharmacokinetics
  • Sponsors Acucela
  • Most Recent Events

    • 15 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 17 Jul 2015 Planned End Date changed from 1 Feb 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 17 Jul 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Sep 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top